Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 2/20 | 0.50 |
| ▸ | JAK2 | O60674 | 2/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.50 |
| ▸ | FLT1 | P17948 | 2/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | CLK2 | P49760 | 2/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.50 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.50 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.50 |
| ▸ | CDK2 | P24941 | 2/20 | 0.50 |
| ▸ | PLK4 | O00444 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | PRKCG | P05129 | 1/20 | 0.50 |
| ▸ | INSR | P06213 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21618384 | 0.83 | AURKA (0.50) | PDPK1AURKAJAK2PRKD3MAP4K4 | |
| SCHEMBL26389859 | 0.83 | DYRK1A (0.50) | PDPK1AURKAJAK2PRKD3MAP4K4 | |
| SCHEMBL857144 | 0.82 | AURKA (0.47) | PDPK1AURKAJAK2PRKD3MAP4K4 | |
| SCHEMBL26673718 | 0.82 | AURKA (0.47) | PDPK1AURKAJAK2PRKD3MAP4K4 | |
| SCHEMBL4440073 | 0.82 | AURKA (0.47) | PDPK1AURKAJAK2PRKD3MAP4K4 | |
| SCHEMBL25304142 | 0.82 | AURKA (0.47) | PDPK1AURKAJAK2PRKD3MAP4K4 | |
| SCHEMBL23087743 | 0.82 | KDR (0.47) | PDPK1AURKAJAK2PRKD3MAP4K4 | |
| SCHEMBL30715979 | 0.82 | AURKA (0.47) | PDPK1AURKAJAK2PRKD3MAP4K4 | |
| SCHEMBL30068918 | 0.82 | AURKA (0.47) | PDPK1AURKAJAK2PRKD3MAP4K4 | |
| SCHEMBL31635966 | 0.81 | AURKA (0.49) | PDPK1AURKAJAK2PRKD3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612424-B2 | HPK1 inhibitors and uses thereof | REGOR PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260108521-A1 | GSPT1 DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2026-04-23 | — | — | US | disclosed |
| EP-4727591-A1 | SMARCA2 DEGRADERS AND USES THEREOF | Astrazeneca AB (SE) | 2026-04-22 | — | — | EP | disclosed |
| US-20250368640-A1 | MULTIPLE KINASE DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2025-12-04 | — | — | US | disclosed |
| EP-4598918-A1 | GSPT1 DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2025-08-13 | — | — | EP | disclosed |
| US-12331046-B2 | CTPS1 inhibitors and uses thereof | NIMBUS CLOTHO, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-4540247-A1 | MULTI-KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2025-04-23 | — | — | EP | disclosed |
| EP-4540246-A1 | MULTIPLE KINASE DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2025-04-23 | — | — | EP | disclosed |
| CN-114555585-B | HPK1 inhibitors and uses thereof | 锐格药业公司 | 2025-02-11 | — | — | CN | disclosed |
| WO-2024256988-A1 | SMARCA2 DEGRADERS AND USES THEREOF | ASTRAZENECA AB (SE) | 2024-12-19 | — | — | WO | disclosed |
| WO-2023023942-A1 | HPK1 INHIBITORS, COMPOSITIONS COMPRISING HPK1 INHIBITOR, AND METHODS OF USING THE SAME | BIOFRONT LTD (CAYMAN) (KY) | 2023-03-02 | — | — | WO | disclosed |
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | REGOR PHARMACEUTICALS, INC. | 2022-12-08 | — | — | US | disclosed |
| EP-3994133-A1 | HPK1 INHIBITORS AND USES THEREOF | Qilu Regor Therapeutics Inc. (CN) | 2022-05-11 | — | — | EP | disclosed |
| WO-2022087634-A1 | CTPS1 INHIBITORS AND USES THEREOF | NIMBUS CLOTHO, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022087634-A1 | CTPS1 INHIBITORS AND USES THEREOF | NIMBUS CLOTHO, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2021249913-A9 | 2'-(QUINOLIN-3-YL)-5',6'-DIHYDROSPIRO[AZETIDINE-3,4'-PYRROLO[1,2-B]PYRAZOLE]-1-CARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS AS MAP4K1 (HPK1) INHIBITORS FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2022-02-03 | — | — | WO | disclosed |
| US-20210299110-A1 | AZAINDOLES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| WO-2021074279-A1 | SPIRO-FUSED TRICYCLIC MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-22 | — | — | WO | disclosed |
| US-10952995-B2 | Azaindoles as inhibitors of HPK1 | GENENTECH, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| WO-2021000935-A1 | HPK1 INHIBITORS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612424-B2 | HPK1 inhibitors and uses thereof | NEK11, NEK1, CSNK1A1 | PDPK1 217/4885AURKA 253/4885JAK2 3692/4885 |
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | HIPK1, SIK1, PGK1 | PDPK1 40/4885AURKA 803/4885JAK2 2508/4885 |
| US-20260108521-A1 | GSPT1 DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | GHSR, GSPT1, GLRA1 | PDPK1 3726/4885AURKA 4178/4885JAK2 3906/4885 |
| US-10952995-B2 | Azaindoles as inhibitors of HPK1 | HIPK1, HIPK2, PPIP5K2 | PDPK1 100/4885AURKA 1578/4885JAK2 3626/4885 |
| US-20250368640-A1 | MULTIPLE KINASE DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | MAP4K1, MAP4K4, MAP4K5 | PDPK1 142/4885AURKA 66/4885JAK2 427/4885 |
| US-12331046-B2 | CTPS1 inhibitors and uses thereof | CTPS1, CTPS2, ECHS1 | PDPK1 775/4885AURKA 2614/4885JAK2 3605/4885 |
| US-20210299110-A1 | AZAINDOLES AS INHIBITORS OF HPK1 | HIPK1, HIPK2, PPIP5K2 | PDPK1 100/4885AURKA 1578/4885JAK2 3626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.